静脉注射免疫球蛋白在儿童风湿性疾病中的规范应用  

Appropriate application of intravenous immunoglobulin in pediatric rheumatic diseases

作　　者：唐红霞 尹薇[1] TANG Hong-xia;YIN Wei(Department of Rheumatology&Immunology,Wuhan Children’s Hospital,Tongji Medical College,Huazhong University of Science&Technolog,Wuhan 430016,China)

机构地区：[1]华中科技大学同济医学院附属武汉儿童医院风湿免疫科,湖北武汉430016

出　　处：《中国实用儿科杂志》2021年第11期816-821,共6页Chinese Journal of Practical Pediatrics

摘　　要：儿童风湿性疾病临床表现多样,确切发病机制尚不详。但许多研究已证实该类疾病属于免疫系统激活介导的自身免疫性疾病。目前还没有针对这些疾病的精准治疗方案。除糖皮质激素、免疫抑制剂和生物制剂外,免疫球蛋白作为多效免疫调节和抗炎制剂,已成为越来越重要的治疗选择,对一线治疗反应差的儿童风湿性疾病显得尤其重要。对于大多数儿童风湿性疾病,静脉注射免疫球蛋白是在双盲随机试验或病例报道的基础上超适应证使用。因此合理规范使用静脉注射免疫球蛋白在儿童风湿性疾病的治疗中显得十分重要。The clinical manifestations of pediatric rheumatic diseases are various,and the exact pathogenesis is still unknown.However,many studies have proved that these diseases are autoimmune diseases mediated by the activation of the immune system.Currently there are no precise treatments for these diseases.In addition to glucocorticoids,immunosuppressants and biological agents,immunoglobulin has become an increasingly important therapeutic option as a versatile immunomodulator and anti-inflammatory agent,especially for poor response to the first line treatment of rheumatic diseases in children.For the majority of pediatric rheumatic diseases,intravenous immunoglobulin is used“off label”on the basis of double-blind randomized trials or case reports.It is very important to establish appropriate and standardized therapy of intravenous immunoglobulin in pediatric rheumatic diseases.

关 键 词：静脉注射免疫球蛋白 机制 风湿性疾病 儿童 

分 类 号：R72[医药卫生—儿科]